Pharmacist demonstration of EpiPen and Anapen autoinjectors to simulated patients: assessment of accuracy.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12614001017617

Enrollment

300

Registered

2014-09-22

Start date

2012-03-12

Completion date

2012-05-04

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Successful treatment of anaphylaxis in the community relies on early and correct use of epinephrine autoinjectors. Community pharmacists supply these devices with and without prescription and have a crucial role teaching patients how to use them. Supply of epinephrine autoinjectors in Australia increased 70-fold in the past decade. New EpiPen and Anapen autoinjectors were launched in Australia in 2011 and 2012, with the potential to cause confusion. However there is no information about how pharmacists demonstrate epinephrine autoinjectors to patients. Therefore the aim of this study was to assess real-world community pharmacist demonstrations of EpiPen and Anapen. We also sought to identify consultation-based predictors of accurate demonstration.

Interventions

This is an observational study of pharmacist practice and performance in demonstrating adrenaline autoinjectors (EpiPen and Anapen) to simulated anaphylaxis patients. Pharmacists were observed during a single consultation where a simulated patient requested advice on how to use an adrenaline autoinjector. Consultations lasted 5-15 minutes.

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Australian pharmacists working in community pharmacies, located within a 20km radius of the Perth Central Business District, and listed on the Pharmacy Registration Board of Western Australia Premises Register.

Exclusion criteria

Pharmacists who are known to the researcher.

Outcome results